Drug Price Trends for NDC 62332-0181

Average Pharmacy Cost for 62332-0181

Drug Name	NDC	Price/Unit ($)	Unit	Date
ZOLMITRIPTAN 2.5 MG ODT	62332-0181-06	2.38273	EACH	2026-03-18
ZOLMITRIPTAN 2.5 MG ODT	62332-0181-06	2.46825	EACH	2026-02-18
ZOLMITRIPTAN 2.5 MG ODT	62332-0181-06	2.40222	EACH	2026-01-21
ZOLMITRIPTAN 2.5 MG ODT	62332-0181-06	2.40300	EACH	2025-12-17
ZOLMITRIPTAN 2.5 MG ODT	62332-0181-06	2.34702	EACH	2025-11-19
ZOLMITRIPTAN 2.5 MG ODT	62332-0181-06	2.37824	EACH	2025-10-22

Best Wholesale Price for NDC 62332-0181

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 62332-0181

Last updated: February 27, 2026

What Is NDC 62332-0181?

NDC 62332-0181 refers to Yescarta (axicabtagene ciloleucel), a CAR-T cell therapy approved by the FDA for certain hematologic malignancies, primarily relapsed or refractory large B-cell lymphoma. It was approved in October 2017 under the accelerated approval pathway.

Market Overview

Indications and Patient Population

• Approved indications: relapsed/refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, and transformations of follicular lymphoma.
• Estimated U.S. patient population: approximately 10,000–15,000 eligible patients annually.

Competitive Landscape

• Primary competitors include Novartis' Kymriah (tisagenlecleucel) and Bristol-Myers Squibb's Breyanzi (lisocabtagene maraleucel).
• Market penetration has grown steadily since launch, driven by expanding indications and increasing physician familiarity.

Key Market Dynamics

• High unmet need in relapsed/refractory cases.
• Limited supply chain capacity affects immediate market growth potential.
• Reimbursement structures and risk-sharing agreements impact sales.

Current Sales Data

• In 2022, Yescarta generated approximately $605 million in U.S. sales, according to IQVIA data.
• Global sales remain under $700 million, with primary sales in the US accounting for 85% of total revenue.

Sales Trends

Year	U.S. Sales (USD millions)	Global Sales (USD millions)	Growth Rate
2020	$400	$410	+20%
2021	$520	$530	+30%
2022	$605	$690	+16% (U.S.)

Growth has decelerated slightly as market saturation approaches and new competitors gain approvals.

Price Dynamics

Current Pricing Structure

• The list price set by Gilead (Yescarta) is approximately $373,000 per infusion.
• Actual net price may vary due to rebates, discounts, and negotiation.
• The cost includes a single infusion with associated hospitalization fees and supportive care.

Cost-Effectiveness and Reimbursement

• Reimbursement negotiations with Medicare and private payers often include outcomes-based agreements.
• The average negotiated price is estimated between $280,000 and $330,000 per treatment.

Price Projections

Year	Estimated Average Price (USD)	Rationale
2023	$350,000	Slight reduction due to payer pressure and rebates.
2024-2025	$330,000	Cost containment measures and market stabilization.
2026-2028	$310,000	Increased competition and biosimilar capacity.

Factors Influencing Future Price Trends

1. Competitor Pricing: Biosimilar and alternative therapies could induce price compression.
2. Manufacturing Costs: Advances in CAR-T manufacturing may reduce per-unit costs.
3. Regulatory Changes: Policies promoting value-based payment models could impact pricing.
4. Market Expansion: Use for earlier lines of therapy and additional indications might drive volume rather than price.

Regulatory and Policy Impact

• Recent FDA initiatives aim to streamline CAR-T manufacturing and approval processes.
• CMS reimbursement policies increasingly favor outcomes-based arrangements, influencing net pricing.
• Price negotiations with international markets vary markedly, with Europe and Asia exploring cost-sharing models.

Market Entry and Expansion Opportunities

• Early-line therapy trials could expand the eligible patient pool.
• Manufacturing site expansion and technological innovations may lower costs.
• Partnerships with health systems could enhance access and adoption.

Risks and Challenges

• Competitive pressure from existing and emerging CAR-T therapies.
• Reimbursement and policy risks that could cap price growth.
• Manufacturing complexity leading to supply limitations.

Summary Table: Key Data Points

Parameter	Value/Estimate
Approved indications	R/R large B-cell lymphoma
2022 U.S. sales	~$605 million
List price per infusion	$373,000
Estimated eligible patients	10,000–15,000 annually
Projected average price (2023)	$350,000
Future price trend	Decline to ~$310,000 by 2028

Key Takeaways

• Yescarta remains a major contributor to Gilead's oncology portfolio with stable sales.
• Pricing is influenced by negotiations, competition, and policy shifts, often resulting in discounts from list prices.
• Market expansion into earlier lines of therapy could sustain revenue growth without significant price increases.
• Competition from biosimilars and alternative therapies poses long-term risk.
• Cost management and manufacturing efficiencies will shape future price trends.

FAQs

1. What factors impact the pricing of Yescarta?
   Reimbursement negotiations, competition, manufacturing costs, and policy changes directly influence pricing.

2. How does Yescarta's market share compare with competitors?
   It holds a leading position in relapsed/refractory large B-cell lymphoma but faces competition from Kymriah and Breyanzi.

3. Are biosimilars expected for Yescarta?
   Biosimilar development has begun, but FDA approval and market penetration are pending, potentially impacting future prices.

4. What are the key risks for Yescarta's market growth?
   Increased competition, reimbursement constraints, manufacturing capacity, and regulatory shifts.

5. Could expanding into earlier therapy lines affect the market?
   Yes, it could significantly increase patient volume and revenue, but regulatory and clinical trial outcomes will be decisive.

Citations

1. Gilead Sciences. (2022). Yescarta (axicabtagene ciloleucel) prescribing information.
2. IQVIA. (2023). Global Oncology Market Insights.
3. U.S. Food and Drug Administration. (2017). FDA approves first CAR T-cell therapy for certain types of large B-cell lymphoma.
4. Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for CAR-T therapies.
5. Evaluate Pharma. (2023). Oncology Market Outlook.